A primary concern is cross-reactivity, where CAR-NK cells target normal cells expressing low levels of TAAs, resulting in on-target, off-tumour toxicity, often demonstrated in CAR-T cell therapies that target antigens like CD19, leading to B-cell aplasia and neurotoxicity due to expression in normal tissues [309]. Here, CD19 is linked to neoplasm.